LS
ACAD icon

Lupo Securities’s Acadia Pharmaceuticals ACAD Stock Holding History

Lupo Securities’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		$7K Buy
22
+9
+69% +$374 0.05% 74
2015
Q2 		$12K Buy
+13
New +$503 0.05% 55

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lupo Securities's ACAD Position: Q2 2015 in Review

Lupo Securities sold out of Acadia Pharmaceuticals (ACAD) in Q2 2015, closing a stake of 1,550 shares — an estimated $60K sold.

Lupo Securities first reported a position in ACAD in Q1 2015 and held it in 1 quarter. The position peaked at $51K in Q1 2015. 188 funds tracked by Wall St. Rank hold ACAD as of Q2 2015.

  • Lupo Securities reported no remaining Acadia Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Lupo Securities sold 1,550 Acadia Pharmaceuticals shares in Q2 2015, an estimated $60K.
  • Lupo Securities first reported a position in Acadia Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Lupo Securities's Acadia Pharmaceuticals position peaked at $51K in Q1 2015.
  • 188 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2015.

Based on Lupo Securities's 13F filing for Q2 2015, filed 14 Aug 2015.